1. Home
  2. BCSF vs EVO Comparison

BCSF vs EVO Comparison

Compare BCSF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bain Capital Specialty Finance Inc.

BCSF

Bain Capital Specialty Finance Inc.

HOLD

Current Price

$13.11

Market Cap

799.8M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.18

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCSF
EVO
Founded
2015
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
799.8M
934.1M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
BCSF
EVO
Price
$13.11
$3.18
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$14.00
$7.00
AVG Volume (30 Days)
428.9K
107.4K
Earning Date
05-05-2026
04-08-2026
Dividend Yield
14.86%
N/A
EPS Growth
N/A
N/A
EPS
1.53
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
$8.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.82
$2.31
52 Week High
$16.00
$4.80

Technical Indicators

Market Signals
Indicator
BCSF
EVO
Relative Strength Index (RSI) 55.61 60.08
Support Level $11.92 $2.87
Resistance Level $14.53 $3.78
Average True Range (ATR) 0.27 0.11
MACD 0.05 0.06
Stochastic Oscillator 55.56 71.91

Price Performance

Historical Comparison
BCSF
EVO

About BCSF Bain Capital Specialty Finance Inc.

Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: